Where others have failed will Atl1102 succeed ?, page-630

Bozz,

Yes it is lots of $$$....and Sarepta's exon skipping drugs only serve 20% of the DMD population in the USA.

Greenfield market - and ANP will have ODD protection of 7 to 10 years exclusivity.

Sarepta is the most logical partner:

- They have PPMD on side
- They have Janet from FDA on side
- Clinical relationships throughout the US
- Extensive patient database
- Logistical footprint in the US for fast GoToMarket once FDA approves
- BIG investors on their register who will back them (Fidelity etc)
- THEY HAVE MOST TO LOSE....because their GT program is stuffed!

.